Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial

Mathis H. Hjelmsø1,5, Shiraz A. Shah1,5, Jonathan Thorsen1, Morten Rasmussen1,2, Gisle Vestergaard3, Martin S. Mortensen3, Asker Brejnrod3, Susanne Brix4, Bo Chawes1, Klaus Bønnelykke1, Søren J. Sørensen3, Jakob Stokholm1 & Hans Bisgaard1*

Maternal dietary interventions during pregnancy with fish oil and high dose vitamin D have been shown to reduce the incidence of asthma and wheeze in offspring, potentially through microbial effects in pregnancy or early childhood. Here we analyze the bacterial compositions in longitudinal samples from 695 pregnant women and their children according to intervention group in a nested, factorial, double-blind, placebo-controlled, randomized trial of n-3 long-chain fatty acids and vitamin D supplementation. The dietary interventions affect the infant airways, but not the infant fecal or maternal vaginal microbiota. Changes in overall beta diversity are observed, which in turn associates with a change in immune mediator profile. In addition, airway microbial maturation and the relative abundance of specific bacterial genera are altered. Furthermore, mediation analysis reveals the changed airway microbiota to be a minor and non-significant mediator of the protective effect of the dietary interventions on risk of asthma. Our results demonstrate the potential of prenatal dietary supplements as manipulators of the early airway bacterial colonization.
Asthma and other chronic inflammatory diseases are a growing burden in the developed world causing substantial morbidity and mortality. There is substantial evidence pointing to the early life as a critical window for disease development, beginning already in the intrauterine environment. This concept was proven in recent clinical trials of dietary interventions with n-3 long-chain polyunsaturated fatty acids (LCPUFA) and high dose vitamin D in pregnancy, resulting in significantly reduced risk of asthma and wheeze in childhood. The mechanisms for these effects are unknown. However, both have been shown to affect the developing immune system; n-3 LCPUFA compete with arachidonic acid-derived eicosanoids, modulate key regulatory cytokines, and is involved in the maturation of Th cells, whereas vitamin D, and associated vitamin D receptors (VDRs), are involved in the maturation of regulatory T-cells (Tregs), the production of antimicrobial peptides, and the production of the tight junction proteins cadherins. In addition to being immune regulatory, n-3 LCPUFA and vitamin D intake have been associated with gut microbial changes in both human observational studies and murine intervention models.

In recent years the human microbiome has received increased attention as a potential contributor to disease development, especially the earliest microbial compositions. In relation to asthma and allergic diseases, both early life bacterial composition in the gut and specific bacterial genera in the neonatal airways and tonsils have been associated with increased disease risk later in life.

The aim of this study is to analyze if maternal supplementation with n-3 LCPUFA and vitamin D affects the microbiota of mother and child. Furthermore, we want to elucidate if the protective effect of these supplementations on asthma can be mediated by the microbiota. This is done using the Copenhagen Prospective Studies on Asthma in Childhood 2010 (COPASAC2010) mother-child cohort, consisting of 736 women and their children participating in a nested factorial randomized clinical trial of n-3 LCPUFA and vitamin D supplementation in pregnancy. Microbiota samples were acquired from the pregnant women (vagina) and at regular intervals during infancy of the child (airways (hypopharyngeal aspirates), and feces) and are in this study analyzed with 16S bacterial rRNA gene amplicon sequencing.

In our study the dietary interventions affects the infant airways, but not the infant fecal or maternal vaginal microbiota. We observe changes in overall beta diversity, which in turn associates with a change in immune mediator profile. The interventions also affects the airway microbial maturation and the relative abundance of specific bacterial genera. Finally, using mediation analysis we observe that the changed airway microbiota is a minor and non-significant mediator of the protective effect of the dietary interventions on risk of asthma.

**Results**

**Study population.** Of the 736 women participating in the COPASAC2010 cohort, 693 were included in the n-3 LCPUFA trial and 580 in the vitamin D trial and delivered at least one microbial sample to our study. 695 children born to these women were included in the n-3 LCPUFA trial and 581 in the vitamin D trial and delivered at least one microbial sample. The same cohort was subject to both interventions in a factorial design with some mothers receiving only placebo, some mothers receiving either supplement, and some mothers receiving both. Randomized allocation among the included women produced comparable groups with respect to baseline characteristics (Table 1).

**Longitudinal development of the microbial community.** We successfully sampled and sequenced the V4 region of the 16S bacterial rRNA gene in 4991 samples, with a mean sequencing depth of 54,682. The total number of unique OTUs found across all samples was 6846 (see Supplementary Table 1). Here follows a short resume of the microbial longitudinal development in the maternal vaginal, and infant fecal and airway samples of the COPASAC2010 mother-child cohort: In the maternal vaginal samples the average bacterial composition in samples from week 24 and 36 appeared similar and were dominated by the genera Lactobacillus and Gardnerella accounting for ~80% and 10% of the sequencing reads, respectively (Fig. 1).

In the infant fecal samples the composition in samples from the infants taken at 1-week and 1-month were dominated by Bifidobacterium, Enterobacteriaceae, and Bacteroides. In the 1-year fecal samples, we observed a significant decrease in Enterobacteriaceae, Staphylococcus, Streptococcus and Bifidobacterium in favor of Bacteroides and a generally larger proportion of overall lower-abundance genera, including Faecalibacterium and Prevotella.

In the infant airway samples the three major genera taken at 1-week after birth were Staphylococcus, Streptococcus and Moraxella. In the subsequent samples from 1-month and 3-months, we observed a gradual increase in the relative abundance of Streptococcus, Moraxella, and Haemophilus, as well as a decrease in Staphylococcus. More details on the individual sample types can be found in previous publications (Mortensen, M. S. et al. Stability of Vaginal microbiota during pregnancy and its importance for early infant microbiota. Unpublished).

**Effects of the n-3 LCPUFA and vitamin D interventions.** The vaginal samples were taken at pregnancy week 36, twelve weeks into the supplementation with n-3 LCPUFA and vitamin D, totaling 665 samples, and did not show any significant differences in alpha diversity as a result of either intervention calculated using the Shannon index (see Supplementary Fig. 1). Similarly, no significant changes in beta diversity were observed in the vaginal samples as a result of the two dietary interventions (Table 2).

The infant fecal microbiota was sampled at 1-week, 1-month, and 1-year after birth, totaling 552, 607, and 625 samples, respectively. No significant effects were seen of the two dietary interventions neither on alpha diversity (Supplementary Fig. 1) nor beta diversity (Table 2) at any of the time points.

Infant airway samples were taken at 1-week, 1-month, and 3-months, totaling 544, 645, and 622 samples, respectively. No effects were seen on alpha diversity at any of the three time points (see Supplementary Fig. 1). However, at 1-month of age, both interventions affected the microbial composition (PERMANOVA, n-3 LCPUFA (F = 3.74, p = 0.005), and Vitamin D (F = 4.228, p = 0.004) (Table 2). No interaction between the two interventions was observed (PERMANOVA, F = 0.49, p = 0.785), and the effect of each intervention remained significant after adjusting for common covariates, which might affect the microbiota (delivery, older siblings, antibiotics during pregnancy, antibiotics in the first month of life, birth season, cat at home at birth, dog at home at birth, and sex). To study the microbial composition effects at 1-month in more detail a differential abundance (DA) analysis was made on the most abundant phyla and genera (Fig. 2). Both interventions led to a significant decrease in Firmicutes and a corresponding increase in Proteobacteria (Fig. 2a, b). These changes seemed mainly to be driven by decreases in the genera Streptococcus and Staphylococcus with an increase in Moraxella, although neither of these individual changes were statistically significant (Fig. 2c, d). In addition, n-3 LCPUFA supplementation resulted in a significant
### Table 1 Baseline characteristics of the n-3 LCPUFA and Vitamin D randomized controlled trials.

| Category          | Variable                          | Overall (n (%) | n-3 LCPUFA (n %) | Placebo (n %) | Vitamin D (n %) | Placebo (n %) |
|-------------------|-----------------------------------|----------------|------------------|---------------|----------------|---------------|
|                   | n 693                             | 344            | 349              | 294           | 286            |               |
| Socioeconomics    | Age; mean (sd)                    | 32.29 (4.36)   | 32.33 (4.27)     | 32.24 (4.46)  | 32.50 (4.33)   | 32.01 (4.32)  |
| (maternal)        | Level of education:               |                |                  |               |                |               |
|                   | Low 55 (7.9)                      | 25 (7.3)       | 30 (8.6)         | 20 (6.8)      | 25 (8.7)       |               |
|                   | Medium 446 (64.4)                 | 221 (64.2)     | 225 (64.5)       | 185 (62.9)    | 189 (66.1)     |               |
|                   | High 192 (27.7)                   | 98 (28.5)      | 94 (26.9)        | 89 (30.3)     | 72 (25.2)      |               |
|                   | Income level:                     |                |                  |               |                |               |
|                   | Low 67 (9.7)                      | 33 (9.6)       | 34 (9.7)         | 27 (9.2)      | 27 (9.4)       |               |
|                   | Medium 366 (52.9)                 | 178 (51.9)     | 188 (53.9)       | 151 (51.4)    | 153 (53.5)     |               |
|                   | High 259 (37.4)                   | 132 (38.5)     | 127 (36.4)       | 116 (39.5)    | 106 (37.1)     |               |
|                   | During pregnancy                  |                |                  |               |                |               |
|                   | Smoking 54 (7.8)                  | 21 (6.1)       | 33 (9.5)         | 20 (6.8)      | 26 (9.1)       |               |
|                   | Cat or dog in home                | 234 (34.1)     | 117 (34.4)       | 117 (33.8)    | 88 (30.3)      | 105 (37.0)    |
|                   | Antibiotic use                    | 253 (36.6)     | 128 (37.3)       | 125 (35.8)    | 102 (34.8)     | 103 (36.0)    |
|                   | Child                             |                |                  |               |                |               |
|                   | Sex (male) 354 (51.1)             | 168 (48.8)     | 186 (53.3)       | 154 (52.4)    | 144 (50.3)     |               |
|                   | Race (caucasian) 664 (95.8)       | 332 (96.5)     | 332 (95.1)       | 282 (95.9)    | 274 (95.8)     |               |
|                   | Season of birth                   |                |                  |               |                |               |
|                   | Winter 212 (30.6)                 | 98 (28.5)      | 114 (32.7)       | 107 (36.4)    | 102 (35.7)     |               |
|                   | Spring 185 (26.7)                 | 94 (27.3)      | 91 (26.1)        | 53 (18.0)     | 53 (18.5)      |               |
|                   | Summer 148 (21.4)                 | 74 (21.5)      | 74 (21.2)        | 62 (21.1)     | 57 (19.9)      |               |
|                   | Fall 148 (21.4)                   | 78 (22.7)      | 70 (20.1)        | 72 (24.5)     | 74 (25.9)      |               |
|                   | Duration of breastfeeding          | 245 (155)      | 249 (159)        | 240 (156)     | 243 (145)      | 247 (165)     |
|                   | Birth                              |                |                  |               |                |               |
|                   | Preterm delivery 27 (3.9)         | 12 (3.5)       | 15 (4.3)         | 10 (3.4)      | 9 (3.1)        |               |
|                   | Nulliparity 318 (45.9)            | 153 (44.5)     | 165 (47.3)       | 121 (41.2)    | 140 (49.0)     |               |
|                   | Antibiotics to mother 221 (32.0)  | 111 (32.4)     | 110 (31.7)       | 97 (33.2)     | 87 (30.5)      |               |
|                   | Antibiotics to child 18 (2.6)     | 10 (2.9)       | 8 (2.3)          | 5 (1.7)       | 9 (3.2)        |               |
|                   | Hospitalized 77 (11.1)            | 39 (11.3)      | 38 (10.9)        | 27 (9.2)      | 27 (9.5)       |               |
|                   | Delivery mode:                    |                |                  |               |                |               |
|                   | Acute CS 84 (12.1)                | 47 (13.7)      | 37 (10.6)        | 39 (13.3)     | 33 (11.5)      |               |
|                   | Vaginal 544 (78.5)                | 266 (77.3)     | 278 (79.7)       | 225 (76.5)    | 226 (79.0)     |               |
|                   | Planned CS 65 (9.4)               | 31 (9.0)       | 34 (9.7)         | 30 (10.2)     | 27 (9.4)       |               |

Percentages or standard deviations in parenthesis. No significant allocation differences were observed (chi-sq or t-test, $p < 0.05$).

---

**Fig. 1** Bacterial community composition in children’s feces and airway, and maternal vaginal samples over time. The community composition is represented by the 12 most abundant genera. Each bar is represented by 544 to 665 samples. Source data are provided as a Source Data file.
decrease in the two genera Gemella and Veillonella (Fig. 2c). An additional DA analysis was performed on OTU level including also less abundant OTUs, hoping to find rare but important taxa affected by the interventions (Supplementary Fig. 2). n-3 LCPUFA significantly (metagenomeSeq, \( p < 0.05 \)) increased the abundance of four OTUs, and decreased the abundance of six OTUs including three Veillonella (Supplementary Fig. 2, and Supplementary Table 2). Vitamin D increased the abundance of six OTUs including two Neisseria and two Haemophilus while decreasing the relative abundance of seven Streptococcus OTUs, five of which was putatively identified a S. pneumoniae, and the rest as S. mitis or S. oralis. However, none of the effects on single OTUs were significant after correcting for multiple testing (FDR, \( p < 0.1 \)). The 1-week and 3-month infant airway samples did not reveal any beta diversity differences between the intervention groups (Table 2).

### Additive effects of n-3 LCPUFA and Vitamin D

Since both interventions showed significant effects on the 1-month airway microbial composition and similar shifts on both phylum and genus levels, the possibility of an additive effect was further explored using a PCoA stratified by the two intervention groups.

### Table 2 The effects of n-3 LCPUFA and Vitamin D vs. placebo on microbial beta-diversity.

| Compartment       | Time point | n-3 LCPUFA F/R2/P-value | Vitamin D F/R2/P-value |
|-------------------|------------|--------------------------|------------------------|
| Maternal vagina   | Week 36    | 1.517/0.002/0.205        | 0.824/0.002/0.399      |
| Child feces       | 1-week     | 0.172/0.001/0.969        | 0.350/0.002/0.955      |
|                   | 1-month     | 0.827/0.001/0.472        | 0.339/0.001/0.865      |
|                   | 1-year      | 1.270/0.002/0.250        | 0.277/0.001/0.973      |
| Child airway      | 1-week     | 0.277/0.001/0.987        | 0.350/0.001/0.955      |
|                   | 1-month     | 4.228/0.007/0.004        | 3.740/0.007/0.005      |
|                   | 3-month     | 0.172/0.000/0.993        | 1.140/0.002/0.297      |

Effects were quantified with F statistics, R2, and P-values, as determined by PERMANOVA on weighted UniFrac distances. Significant p-values (\( p < 0.05 \)) are shown in bold.
account for an estimated 9% of the total asthma prevention effect till age 5 years \((p = 0.11)\) previously published\(^8\). Similarly, 5.5% of the previously published vitamin D effect on persistent wheeze till 3 years of age could be mediated by changes in the 1-month airway microbiota \((p = 0.39)\). However, none of the minor mediation effects were statistically significant, suggesting that the microbial changes observed as a result of the two dietary supplements had a minor or no effect on later risk of asthma.

**The interventions and gut and airway microbial maturation.** As early microbial colonization patterns have previously been linked to later health outcomes we wanted to study the influence of the interventions on the early life microbial maturation. To do that we calculated the microbiota-by-age z-score \((MAZ)\) for the gut and airway samples, with both compartments represented by three sampling time points\(^23\). No effect of either intervention on MAZ was seen on any of the gut samples, and on the 3-month airway samples. However, n-3 LCPUFA decreased the airway maturation in the 1-week time point \((t\text{-}test, p = 0.004)\), and increased the maturation in the 1-month time point \((t\text{-}test, p = 0.01)\). The Vitamin D intervention had a weaker and not significant effect, although the same trend was observed at both timepoints. An additive effect of the interventions was also observed decreasing the MAZ with 0.2 per intervention \((p = 0.007)\) at the 1-week and increasing with 0.1 per intervention \((p = 0.05)\) at 1-month.

**Interventions, airway microbiota, and airway immunology.** To study the mechanism of the observed changes in airway microbiota in the 1-month time point, we analyzed the association between PCO1 from Fig. 3, affected by both interventions, and airway immunology taken at the same time point. We found a significant positive association between PCO1 and CCL4, TNF-\(\alpha\), CXCL8, and IL-1\(\beta\), and a significant negative association between PCO1 and CCL2, and CCL17 (Fig. 5).

**Effect modulation by mode of delivery.** To investigate possible mechanisms of the intervention effects on the 1-month airway microbiota, we examined potential effect modulation by mode of delivery. If the interventions had direct effects on the maternal gut microbiota, an assumed transfer to the child could be interrupted by cesarean section delivery. However, no significant interaction was observed neither for delivery mode on the global beta diversity variation \((adonis, p = 0.58)\) nor the shift in PCO1 (linear model, \(p = 0.29)\) of the 1-month airway samples.

**Discussion**

Third trimester supplementation with n-3 LCPUFA and high dose vitamin D had significant effects on the infant 1-month airway microbiota, with the interventions affecting the overall population structure and relative abundances of individual genera in a similar and additive manner. This suggests that both micronutrients share a common pathway modifying the infant airway microbiota. Alternatively, both lack of n-3 LCPUFA and vitamin D could be limiting factors of a general optimal fetal immune development, which would explain the observed parallel bacterial effects. Yet, such additive effects were not seen in our clinical end-points.

The effects of the interventions affected the relative abundance of several bacterial genera previously associated with inflammation, asthma and wheeze. The n-3 LCPUFA intervention resulted in a significant reduction in *Gemella* and *Veillonella* (Fig. 2), both positively associated with the development of asthma in a previous study of the same cohort\(^24\). Furthermore, in our study, a reduction in the genus *Streptococcus* was found to be significant.
in the additive model of the two interventions, and the abundance of seven *Streptococcus* OTUs both belonging to pathogenic and commensal species were significantly reduced as an effect of Vitamin D (Supplementary Fig. 2, and Supplementary Table 2).

This genus has previously been associated with later asthma development when detected in the airways during early infancy\(^19,25\). *Streptococcus*-rich, *Gemella*-rich, and *Veillonella*-rich bacterial compositions have been shown to associate with an...
inflammatory phenotype in healthy adults, with increasing levels of Th17 cytokines including IL-1α and IL-1β. In addition, Veillonella has been shown to correlate positively with a number of inflammatory cells and exhaled nitric oxide (eNO), further suggesting a causal relationship between a distinct airway microbiota, systemic and topical inflammation, and asthma pathogenesis.

While we found significant effects on the 1-month airway microbiota, there were no effects on the 1-week and 3-month time points. The very dynamic initial colonization and development of the airway microbiota, as described previously, may in part explain this. This was also apparent in the effect of the interventions on airway maturation, possibly influencing colonization progression in the dynamic period of our two earliest time points, but no longer detectable at the 3-month time point, shown in the literature to be a more stable period in airway microbial development. However, the airway MAZ index did not associate with later asthma risk, suggesting that the maturation effects might be a side effect of the interventions clinical effects instead of the cause. The speculated immune-priming effects of the interventions and the observed clinical effects across the 1-month window suggests that the observed mechanism could penetrate in a certain so-called “window of opportunity” in early infancy; a period where the developing immune system and the highly dynamic airway microbiota mutually influence each other. This time-sensitivity has been observed in several other microbiome studies, although the precise demarcations of such windows are not yet clearly defined. Interestingly, there were no detectable effects on the maternal vaginal microbiota in pregnancy, nor the early gut microbiota of the children, which for Vitamin D has been observed before in a similar high dose vitamin D cohort study.

The mechanism whereby the interventions affected the airway bacteria of the neonates of our study is still unknown, although we observed strong associations between the airway microbiota composition most affected by the interventions and several immune mediators including proinflammatory TNF-α and IL-1β. This could suggest that a more active and stimulated young immune profile affected the colonization pattern of the early airways, which has been linked to a reduced risk of inflammatory diseases in later life. However, the direction of causality could also be opposite, with specific bacteria leading to a properly stimulated immune maturation. Several other possible mechanisms can be found in the literature, e.g., with n-3 LCPUFAs being known for their anti-inflammatory effects, and the modulation of eicosanoid mediator synthesis is the likely primary mode of action related to asthma pathogenesis. LCPUFAs have also been linked to a range of other anti-inflammatory mechanisms including the production of resolvins and protectins, and the reduction of pro-inflammatory mediators and oxidative stress. It is unclear whether the maternal supplement only worked through a fetal priming effect or if higher levels were still present after birth, directly affecting the child immune cells.

We have previously demonstrated that the vitamin D supplementation upregulated local immune mediators in the airways related to type 1, type 2, type 17, and regulatory immune paths, at the age of 1-month, which could influence the bacterial colonization dynamics, but the changes in the airway microbiota, as demonstrated in this study, could also be interacting with the immune maturation as discussed previously. Another possible pathway is an increased production of the antimicrobial peptides cathelicidin and β-defensin by the bronchial epithelial cells, which is stimulated by the hormonally active form of vitamin D.

Despite affecting airway bacteria previously associated with inflammatory diseases, our results suggest that only a minor part of the protective effect on asthma/persistent wheeze from the prenatal n-3 LCPUFA (9%) and high-dose vitamin D (5%) supplementations could be explained by the observed early life microbial alterations in the airways, and this effect is uncertain as none of the mediation effects reached statistical significance. However, we believe that this is mainly a power issue as the overall clinical effects of n-3 LCPUFA just reaches significance. Splitting this effect into mediated (via microbiota) and direct (not mediated by microbiota), renders significance hard to achieve, as the clinical effects of n-3 LCPUFA is probably working through many different mechanistic pathways. These could include changes in fetal development including lung organogenesis, immune maturation and modulation of DNA methylation states.

The major advantage of this study is that the effects of n-3 LCPUFA and vitamin D on the maternal and infant microbiota were tested in a double blind randomized clinical trial, reducing the risk of possible confounding inherent to observational studies. Another strength of this study is the clinical surveillance of the COPSAC2010 cohort, including longitudinal sampling from 695 mother-child pairs. All study participants were investigated by the same investigators ensuring comparable measurements in regard to both microbiota sampling and clinical diagnosis of asthma and persistent wheeze. It is another strength that several biological compartments were sampled in this study, including maternal vaginal and infant gut and airways. It is a limitation that additional compartments, including the maternal gut before and after intervention and infant microbiota right after birth, were not sampled. This would have allowed us to detect a possible fecal bacterial transfer event during birth. However, an intervention manipulated maternal bacterial transfer during delivery was not observed in this study as the intervention effects were not modified by cesarean section. In addition, closer airway sampling around the 1-month time point could have helped in pinpointing the exact period of the effect of the two interventions. This study was performed using 16S RNA gene amplicon sequencing, characterizing the effects of the interventions on the bacterial community composition, which does not cover possible effects on fungi, parasites and viruses inhabiting the human body. In addition, the technique is insensitive to functional differences between communities, which could be explored further in future studies employing metagenomic sequencing.

**Methods**

**Experimental design.** The study was embedded in the population-based COPSAC2010 prospective mother-child cohort of 736 women and their children followed from week 24 of pregnancy, with the primary clinical endpoint persistent wheeze or asthma, which was diagnosed according to a previously validated quantitative algorithm.

**Microbial sampling.** Maternal vaginal swabs were sampled at the research unit at week 24 and 36 of pregnancy. The infant airway was sampled using hypopharyngeal aspirates obtained at ages 1-week, 1-month, and 3-months, using a soft suction catheter passed through the nose. Infant fecal samples were collected 1-week, 1-month, and 1-year after birth, either at the research clinic or by the parents at home using detailed instructions. Each fecal sample was mixed on arrival with 10% vol/vol glycerol broth. All samples were stored at −80 °C until DNA extraction.

**Immunological sampling.** Airway immunology was assessed 1-month after birth by measuring unstimulated levels of 20 cytokines and chemokines in airway mucus lining fluid sampled by nasosorption. Briefly, a synthetic absorptive membrane (Fibrocell hydroxylated polyester sheets, Accudyn Ultra (cat no. SPR0730), Pall Life Sciences, Portsmouth, Hampshire, UK) was inserted in both nostrils for 2 min and stored at −80 °C until protein extraction, which was done by immersing both filter strips in 300 μL Milliplex assay buffer (Millipore, cat no. L-AB, Mass) containing 1 protease inhibitor tablet (Roche) per 25 mL buffer, and then transferred to the cup of a cellulose acetate tube filter (0.22 μm) placed in an Eppendorf tube (Spin X centrifuge tube filter, cat no. CLS8161, Sigma-Aldrich, St Louis, Mo). The tube was centrifuged for 5 min at 16,000xg, 4 °C. The obtained protein extract
was stored immediately at −80°C until determination of immune mediators (cytokines and chemokines) using high-sensitivity electrochemiluminescence multiplex assay (Enzyme Immunoassay Code Discovery). The 20 cytokines and chemokines include interleukin (IL)-12p70, CXCL10 (interferon gamma-induced protein [IP]-10), interferon (IFN)-γ, tumor necrosis factor (TNF)-α, CCL4 (macrophage inflammatory protein [MIP]-1B), CCL2 (monocyte chemotactic protein [MCP]-1), CCL13 (MCP-4), IL-4, IL-5, IL-13, C11L (eosinatin-1), CCL26 (eosinatin-3), CCL22 (CCR4 receptor and activated chemokine [TARC]), CCL24 (macrophage-derived chemokine [MDC]), IL-17, IL-1β, CXCL8 (IL-8), transforming growth factor (TGF)-β1, IL-10, and IL-2.

Ethics. The study was conducted in accordance with the guiding principles of the Declaration of Helsinki and was approved by the National Committee on Health Research Ethics (H-B-2008-093 and H-B-2009-014), the Danish Data Protection Agency (2015-41-3696), and Danish Health and Medicines Authority (2612-3959). Both parents gave oral and written informed consent before enrolment. The trials are registered with ClinicalTrials.gov, identifier: NCT00798226 and NCT00856947.

Dietary supplements. The women were randomized 1:1 to a daily dose of 2.4 g of n-3 LCPUFA (55% EPA and 37% DHA) in triacylglycerol form (Incomerga TG33/22, Croda Health Care) or placebo (olive oil, containing 72% n-9 oleic acid and 12% n-6 linoleic acid (Pharma-Tech A/S)), given from pregnancy week 24 to 1 week postpartum3. In addition, the women were randomized 1:1 to a daily dose of 2400 IU vitamin D3 supplementation or matching placebo tablets (Camest A/S) from pregnancy week 24 to 1 week postpartum. All women were instructed to continue supplementation of 400 IU of vitamin D3 during pregnancy as recommended by the Danish National Board of Health; thus, the study is a dose comparison of 2800 IU/d vs. 400 IU/d of vitamin D3 supplementation. These two interventions were crossed in a factorial design, yielding four groups (n-3 LCPUFA/vitamin D, n-3 LCPUFA/placebo, placebo/vitamin D and placebo/placebo).

DNA extraction, sequencing, and bioinformatics. The DNA was extracted using the Mobio PowerMag soil DNA isolation kit on the epMotion 5075 robotic platform according to manufacturer’s protocol. Extracted DNA was amplified using a two-step PCR reaction with the 16S rRNA gene primers 515 F (5′-GTGCCAGCMGCCGCGGTAA-3′) and 806 R (5′-GGACTACHVGGGTWTCTAAT-3′) targeting the V4 region27. The PCR conditions for the first PCR-step were 2 min of denaturation at 94°C, followed by 30 cycles of 20 s at 94°C (denaturing), 30 s at 56°C (annealing), and 40 s at 68°C (elongation), with a final extension at 68°C for 5 min. In the second PCR-step the sequencing primers and adapters were added using the PCR conditions as above but with only 15 cycles. Finished libraries were quantified, equimolarity pooled and concentrated using the DNA Clean & Concentrator-11 (Zymo Research, Irvine, CA, USA) according to the manufacturer’s instructions. Sequencing was done on the Miseq platform using the v2 kit (paired-end 250 bp reads). Sequencing reads were demultiplexed by the Miseq Controller Software, trimmed using biopieces49, checked for chimeras using usescr30,31,32, and classified using Mothur53,18.

Statistical analysis. All data analyses were conducted using the statistical software R 3.3.359. Samples with less than 2000 reads (n = 146, 7.5%) were omitted from the analyses. Sequencing reads were quality filtered, taxonomic agglomeration, alpha diversity (analyzed using the Shannon Index) and beta diversity (analyzed using weighted UniFrac distances58) estimates were done using the R-package “phyloseq”56. Differences in beta diversity were tested using permutational multivariate analysis of variance (PERMANOVA)50 with 10,000 permutations and visualized with principal coordinates analysis (PCoA) plots. Differential abundance was tested with the Wilcoxon rank sum test on phylum level and with the specialized tool for DA analysis of sparse data, the metagenomeSeq feature-model58, and controlled using False Discovery Rate Control by Benjamini-Hochberg and significance thresholds were reported at level 0.1 owing to the exploratory nature of the study. 17 OTU clusters were identified using the default NCBI nr/nt database, and all named bacterial hits with highest % identity and % query coverage was reported. Multiple inferences were controlled on genus and OTU level using dietary supplement as predictor, after

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Summary and feature-level data underlying Figs. 1–5, and Supp Figs. 1, 2 are provided as Source Data files. The 16S rRNA gene sequences are publicly available at Sequence Read Archive (SRA) [https://www.ncbi.nlm.nih.gov/sra/] with the accession numbers PRIN4A40273, PRIN4A41753, PRIN5A76765, and PRIN5A759012. All other data that supports the findings in this study, including clinical data, are available from the corresponding author upon reasonable request. Participant-level personally identifiable data are protected under the Danish Data Protection Act and European Regulation 2016/679 of the European Parliament and of the Council (GDPR) that prohibit distribution even in pseudo-anonymized form, but can be made available under a data transfer agreement as a collaboration effort.

Received: 16 November 2018; Accepted: 10 December 2019; Published online: 22 January 2020

References

1. WHO | Global status report on noncommunicable diseases 2014. (2015).
2. Blümer, N. & Renz, H. Consumption of omega-3-fatty acids during perinatal life: role in immuno-modulation and allergy prevention. J. Perinat. Med. 35, S12–S18 (2007).
3. Bisgaard, H. et al. Fish oil-derivated fatty acids in pregnancy and wheeze and asthma in offspring. N. Engl. J. Med. 375, 2533–2539 (2016).
4. Chawes, B. L. et al. Effect of vitamin D3 supplementation during pregnancy on risk of persistent wheeze in the offspring: a randomized clinical trial. JAMA 315, 353–361 (2016).
5. Litonjua, A. A. et al. Effect of prenatal supplementation with vitamin D on asthma or recurrent wheezing in offspring by age 3 years: the VDAART randomized clinical trial. JAMA 315, 363–370 (2016).
6. Wolsk, H. M. et al. Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials. PLoS ONE 12, e0186557 (2017).
7. Klemens, C. M., Berman, D. R. & Mozurkewich, E. L. The effect of perinatal omega-3 fatty acid supplementation on inflammatory markers and allergic disease: a systematic review. JBI 118, 916–925 (2015).
8. Dennis, E. A. & Norris, P. C. Eicosanoid storm in infection and inflammation. Nat. Rev. Immunol. 15, 511–523 (2015).
9. Clark, A. & Mach, N. Role of vitamin D in the hygiene hypothesis: the interplay between vitamin D, vitamin D receptors, gut microbiota, and immune response. Front. Immunol. 7, 627 (2016).
10. Zhang, Y.-G., Wu, S. & Sun, J. Vitamin D, vitamin D receptor, and tissue remodeller. Clin. Ther. 36, 475–496 (2014).
11. Baeke, F., Takishii, T., Korf, H., Gysemans, C. & Mathieu, C. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 10, 482–496 (2010).
12. Jin, D. et al. Lack of vitamin D receptor causes dysbiosis and changes the functions of the murine intestinal microbiome. Clin. Ther. 37, 996–1009.e7 (2015).
13. Luthold, R. V., Fernandes, G. R., Franco-de-Moraes, A. C., Folchetti, L. G. D. & Ferreira, S. R. G. Gut microbiota interactions with the immunomodulatory role of vitamin D in normal individuals. Metabolism 69, 76–86 (2014).
14. Ghosh, S. et al. Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and inflammatory colitis but impairs LPS dephosphorylation activity causing sepsis. PLoS ONE 8, e55468 (2013).
15. Bisgaard, H., Bennølykke, K. & Stokholm, J. Immune-mediated diseases and microbial exposure in early life. Clin. Exp. Allergy 44, 475–481 (2014).
16. Stokholm, J. et al. Maturation of the gut microbiome and risk of asthma in early childhood. Nat. Commun. 9, 141 (2018).
17. Bisgaard, H. et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J. Allergy Clin. Immunol. 128, 646–652.e5 (2011).
18. Arrieta, M.-C. et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci. Transl. Med. 7, 307ra152 (2015).
19. Bisgaard, H. et al. Childhood asthma after bacterial H. pylori colonization of the airway in neonates. N. Engl. J. Med. 357, 1487–1495 (2007).
20. von Linstow, M.-L. et al. Neonatal airway colonization is associated with troublesome lung symptoms in infants. Am. J. Respir. Crit. Care Med. 188, 1041–1042 (2013).
21. Bisgaard, H. et al. Deep phenotyping of the unselected COPSAC2010 birth cohort study. Clin. Exp. Allergy 43, 1384–1394 (2013).
22. Mortensen, S. M. et al. The developing hypopharyngeal microbiota in early life. Microbiome 4, 70 (2016).
23. Subramanian, S. et al. Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature 510, 417–421 (2014).
24. Thorsen, J. et al. Infant airway microbiota and topical immune perturbations in the origins of childhood asthma. Nat. Commun. 10, 1–8 (2019).
25. Teo, S. M. et al. The infant nasopharyngeal microbiota impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe 17, 704–715 (2015).
26. Segal, L. N. et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat. Microbiol. 1, 16031 (2016).
27. Segal, L. N. et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome 1, 19 (2013).
28. Bosch, A. A. T. M. et al. Development of upper respiratory tract microbiota in infants is affected by mode of delivery. Ebiomedicine 9, 336–345 (2016).
29. Bosch, A. A. T. M. et al. Maturation of the infant respiratory microbiota, environmental drivers, and health consequences: a prospective cohort study. Am. J. Respir. Crit. Care Med. 196, 1582–1590 (2017).
30. Gensollen, T., Iyer, S. S., Kasper, D. L. & Blumberg, R. S. How colonization by bacteria during the first 3 months: findings from the ethnically diverse Vitamin D Antenatal Asthma Reduction Trial (VANDART). J. Allergy Clin. Immunol. 139, 482–491.e14 (2017).
31. Prescott, S. L. Early-life environmental determinants of allergic diseases and the wider pandemic of inflammatory noncommunicable diseases. J. Allergy Clin. Immunol. 131, 23–30 (2013).
32. Prescott, S. L. Early nutrition as a major determinant of ‘Immunne Health’: implications for allergy, obesity and other noncommunicable diseases. Nestl Nutr. Inst. Workshop Ser. 85, 1–17 (2016).
33. Maroon, J. C. & Bost, J. W. Omega-3 fatty acids (fish oil) as an anti-inflammatory: an alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. Surg. Neurol. 65, 326–331 (2006).
34. Giudetti, A. M. & Cagnazzo, R. Bäckhed, F. et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17, 690–703 (2015).
35. Dominguez-Bello, M. G. et al. Delivery mode shapes the acquisition and structure of the infant microbiota across multiple body habitats in newborns. Proc. Natl Acad. Sci. USA 107, 11971–11975 (2010).
36. Lloyd-Price, J. et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature 550, 61–66 (2017).
37. Stokholm, J. et al. Antibiotic use during pregnancy alters the Commensal vaginal microbiota. Clin. Microbiol. Infect. 20, 629–635 (2014).
38. Claussen, B. J. A novel method for assessing unchallenged levels of mediators in nasal epithelial lining fluid. J. Allergy Clin. Immunol. 125, 1387–1389.e3 (2010).
39. Folsaag, N. V. et al. Neonatal cytokine profile in the airway mucosal lining fluid is skewed by maternal atopy. Am. J. Respir. Crit. Care Med. 185, 275–280 (2012).
40. Folsaag, N. V. et al. Pathogenic bacteria colonizing the airways in asymptomatic neonates stimulates topical inflammatory mediator release. Am. J. Respir. Crit. Care Med. 187, 589–595 (2013).
41. Hansen, M. A. Biopieces [Internet]. www.biopieces.org (2015).
42. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461 (2010).
43. Haas, B. J. et al. Chimeric 16S RNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 21, 494–504 (2011).
44. Edgar, R. C. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat. Methods 10, 996–998 (2013).
45. Schloss, P. D. et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75, 7537–7541 (2009).
46. Chawes, B. L. K. et al. A novel method for assessing unchallenged levels of inflammatory mediator release. Am. J. Respir. Crit. Care Med. 185, 275–280 (2012).
47. Almeida, R. S. et al. Clustering of asymptomatic neonates stimulates topical inflammatory mediator release. Am. J. Respir. Crit. Care Med. 187, 589–595 (2013).
48. Thorsen, J. et al. Infant airway microbiota and topical immune perturbations in the origins of childhood asthma. Nat. Commun. 10, 1–8 (2019).
49. Teo, S. M. et al. The infant nasopharyngeal microbiota impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe 17, 704–715 (2015).
50. Segal, L. N. et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat. Microbiol. 1, 16031 (2016).
51. Segal, L. N. et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome 1, 19 (2013).
52. Bosch, A. A. T. M. et al. Development of upper respiratory tract microbiota in infants is affected by mode of delivery. Ebiomedicine 9, 336–345 (2016).
53. Bosch, A. A. T. M. et al. Maturation of the infant respiratory microbiota, environmental drivers, and health consequences: a prospective cohort study. Am. J. Respir. Crit. Care Med. 196, 1582–1590 (2017).
54. Gensollen, T., Iyer, S. S., Kasper, D. L. & Blumberg, R. S. How colonization by bacteria during the first 3 months: findings from the ethnically diverse Vitamin D Antenatal Asthma Reduction Trial (VANDART). J. Allergy Clin. Immunol. 139, 482–491.e14 (2017).
55. Prescott, S. L. Early-life environmental determinants of allergic diseases and the wider pandemic of inflammatory noncommunicable diseases. J. Allergy Clin. Immunol. 131, 23–30 (2013).
56. Prescott, S. L. Early nutrition as a major determinant of ‘Immunne Health’: implications for allergy, obesity and other noncommunicable diseases. Nestl Nutr. Inst. Workshop Ser. 85, 1–17 (2016).
57. Maroon, J. C. & Bost, J. W. Omega-3 fatty acids (fish oil) as an anti-inflammatory: an alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. Surg. Neurol. 65, 326–331 (2006).
58. Giudetti, A. M. & Cagnazzo, R. Bäckhed, F. et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17, 690–703 (2015).
59. Dominguez-Bello, M. G. et al. Delivery mode shapes the acquisition and structure of the infant microbiota across multiple body habitats in newborns. Proc. Natl Acad. Sci. USA 107, 11971–11975 (2010).
60. Lloyd-Price, J. et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature 550, 61–66 (2017).
61. Stokholm, J. et al. Antibiotic use during pregnancy alters the Commensal vaginal microbiota. Clin. Microbiol. Infect. 20, 629–635 (2014).
62. Claussen, B. J. A novel method for assessing unchallenged levels of mediators in nasal epithelial lining fluid. J. Allergy Clin. Immunol. 125, 1387–1389.e3 (2010).
